December 3, 2025

Molecular

We’re excited to share some enhancements to our next-generation sequencing (NGS) panels, NeoTYPE^® CLL Profile and NeoTYPE^® Ovarian Tumor Profile. Effective Monday, December 8, these panels will be updated with additional biomarkers, as specified below, delivering broader coverage and enhanced diagnostic precision. These additions will be applied to both new and in-flight cases.

• NeoTYPE CLL Profile
  • NEW Genes: B2M, BRAF, FBXW7, KRAS, MED12, NRAS, POT1, XPO1, and ZMYM3
  • Clinical Significance: These genes expand the panel's coverage to include emerging biomarkers that aid in diagnosis, prognosis, and therapeutic management for a more robust assessment.
• NeoTYPE Ovarian Tumor Profile
  • NEW Genes: FOXL2
  • Clinical Significance: FOXL2 mutations are present in over 95% of adult granulosa cell tumors (AGCT) of the ovary¹, making them a highly specific diagnostic marker. Including FOXL2 aids in accurately identifying AGCTs, supporting precise diagnosis and improved patient care.

Turnaround times, CPT Codes, pricing, and NYS approvals remain the same.

1. cap.org/member-resources/pathology-case-challenge/adult-granulosa-cell-tumor

IDHNow for AML Sponsored Testing Program

Effective December 31, 2025, the Servier IDHNow for AML sponsored testing program, providing expedited IDH1 profiling results for eligible AML patients, will be discontinued. Orders received and accessioned between now and December 31 will be processed through the IDHNow for AML sponsored testing program as normal. NeoGenomics will continue to offer testing solutions for AML patients, including IDH1 and IDH2 testing, and support oncologists in making informed treatment decisions.

To learn more and order today, please visit our website.
For any questions on the discontinuation of this program or for more information, please contact your local NeoGenomics Sales Consultant or our Client Services team at (866) 776-5907, option 3.   

Comprehensive Testing for MDS, CMML, and Other Myeloid Disorders

Comprehensive genomic profiling (CGP) plays a pivotal role in differentiating disease subtypes and resolving complex diagnostic challenges associated with MDS and CMML. Neo Comprehensive® – Myeloid Disorders, a guideline-driven CGP assay, uses DNA and RNA next-generation sequencing (NGS) to detect relevant aberrations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance for MDS, CMML, and other myeloid disorders, enhancing clinical decision-making and driving informed care.

Learn more about the Neo Comprehensive – Myeloid Disorders test.

c-MET for NSCLC

NeoGenomics offers a c-MET CDx for NSCLC -- an advanced immunohistochemistry (IHC) assay that enables precise detection of MET protein expression, empowering oncologists to identify patients with NSCLC who may benefit from a new targeted therapy.

Approximately 25% of patients with EGFR wild-type, non-squamous NSCLC have c-MET protein overexpression; and half of those patients have high c-MET overexpression – defined as ≥ 50% of tumor cells with strong (3+) staining by immunohistochemistry (IHC) test.¹

Learn how c-MET testing can transform your approach to lung cancer care. We invite you to visit us online.

1. Camidge DR, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein–overexpressing advanced nonsquamous EGFR-wildtype non–small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024;42:3000-3011. doi:10.1200/JCO.24.00720